ATNM Quote, Trading Chart, Actinium Pharmaceuticals Inc.
home / stock / atnm / atnm quote
$7.75 Last:
-2.27% Change Percent:
$7.87 Open:
$7.75 Previous Close:
$7.93 High:
$7.05 Low:
524,059 Volume:
03/05/2021 04:57:20 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-05 | 7.87 | 7.75 | 7.93 | 7.05 | 524,059 |
| 2021-03-04 | 8 | 7.93 | 8.14 | 7.54 | 380,360 |
| 2021-03-03 | 8.15 | 8.01 | 8.25 | 7.93 | 374,857 |
| 2021-03-02 | 8.01 | 8.15 | 8.18 | 7.91 | 149,475 |
| 2021-03-01 | 8.2 | 8.06 | 8.33 | 8 | 208,414 |
| 2021-02-26 | 7.9 | 8.06 | 8.25 | 7.7 | 334,913 |
| 2021-02-25 | 8.19 | 7.87 | 8.3 | 7.785 | 449,727 |
| 2021-02-24 | 8.17 | 8.13 | 8.3 | 8 | 243,933 |
| 2021-02-23 | 8.07 | 8.15 | 8.31 | 7.61 | 497,833 |
| 2021-02-22 | 8.82 | 8.26 | 8.95 | 8.26 | 632,402 |
| 2021-02-19 | 9.02 | 8.81 | 9.02 | 8.69 | 307,385 |
| 2021-02-18 | 9.1 | 8.82 | 9.21 | 8.65 | 421,566 |
| 2021-02-17 | 9.33 | 9.27 | 9.41 | 9.07 | 410,853 |
| 2021-02-16 | 9.4 | 9.36 | 9.6 | 9.1989 | 335,279 |
| 2021-02-15 | 9.23 | 9.25 | 9.31 | 9.091 | 285,122 |
| 2021-02-12 | 9.23 | 9.25 | 9.31 | 9.091 | 276,918 |
| 2021-02-11 | 9.47 | 9.23 | 9.56 | 9.09 | 193,832 |
| 2021-02-10 | 9.84 | 9.47 | 9.8892 | 8.76 | 476,717 |
| 2021-02-09 | 9.85 | 9.5 | 10.15 | 9.35 | 636,172 |
| 2021-02-08 | 9.62 | 9.79 | 9.82 | 9.52 | 537,339 |
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
-
Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer - Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions - Proven deal making abilities in the empowered antibody, biologics and gen...
-
Actinium Announces Participation in H.C. Wainwright Global Life Sciences Conference PR Newswire NEW YORK , March 2, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that management will participate in the ...
-
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting ...